Park National Corp OH cut its position in shares of Stryker Corporation (NYSE:SYK) by 1.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,832 shares of the medical technology company’s stock after selling 338 shares during the period. Park National Corp OH’s holdings in Stryker Corporation were worth $2,475,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Nomura Asset Management Co. Ltd. raised its stake in shares of Stryker Corporation by 201.5% in the first quarter. Nomura Asset Management Co. Ltd. now owns 407,978 shares of the medical technology company’s stock worth $53,711,000 after buying an additional 272,680 shares in the last quarter. Columbia Partners L L C Investment Management raised its stake in shares of Stryker Corporation by 13.1% in the first quarter. Columbia Partners L L C Investment Management now owns 25,682 shares of the medical technology company’s stock worth $3,381,000 after buying an additional 2,982 shares in the last quarter. HM Payson & Co. raised its stake in shares of Stryker Corporation by 13.0% in the first quarter. HM Payson & Co. now owns 4,116 shares of the medical technology company’s stock worth $542,000 after buying an additional 475 shares in the last quarter. Pointe Capital Management LLC acquired a new stake in shares of Stryker Corporation during the first quarter worth approximately $271,000. Finally, Achmea Investment Management B.V. acquired a new stake in shares of Stryker Corporation during the first quarter worth approximately $2,307,000. 73.79% of the stock is currently owned by hedge funds and other institutional investors.
Stryker Corporation (NYSE:SYK) traded up 0.61% during trading on Tuesday, hitting $146.89. 249,039 shares of the company’s stock traded hands. Stryker Corporation has a 52-week low of $106.48 and a 52-week high of $148.84. The company’s 50 day moving average price is $143.85 and its 200 day moving average price is $135.90. The company has a market cap of $54.95 billion, a PE ratio of 32.79 and a beta of 0.80.
Stryker Corporation (NYSE:SYK) last released its earnings results on Thursday, July 27th. The medical technology company reported $1.53 EPS for the quarter, topping the Zacks’ consensus estimate of $1.51 by $0.02. The company had revenue of $3.01 billion for the quarter, compared to analysts’ expectations of $2.98 billion. Stryker Corporation had a return on equity of 24.26% and a net margin of 14.22%. The business’s revenue for the quarter was up 6.1% compared to the same quarter last year. During the same period in the previous year, the business posted $1.39 EPS. Analysts expect that Stryker Corporation will post $6.50 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 31st. Stockholders of record on Friday, September 29th will be paid a dividend of $0.425 per share. This represents a $1.70 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date of this dividend is Thursday, September 28th. Stryker Corporation’s payout ratio is 37.95%.
TRADEMARK VIOLATION NOTICE: “Park National Corp OH Cuts Position in Stryker Corporation (SYK)” was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another publication, it was stolen and reposted in violation of international trademark & copyright legislation. The correct version of this report can be viewed at https://stocknewstimes.com/2017/08/15/park-national-corp-oh-cuts-position-in-stryker-corporation-syk.html.
A number of brokerages have recently commented on SYK. BidaskClub lowered shares of Stryker Corporation from a “buy” rating to a “hold” rating in a research report on Monday, July 31st. Cowen and Company reissued a “buy” rating and issued a $160.00 price objective (up previously from $150.00) on shares of Stryker Corporation in a research report on Sunday, July 30th. Oppenheimer Holdings, Inc. set a $148.00 price objective on shares of Stryker Corporation and gave the stock a “hold” rating in a research report on Friday, July 28th. Zacks Investment Research lowered shares of Stryker Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, July 27th. Finally, Royal Bank Of Canada boosted their price objective on shares of Stryker Corporation from $140.00 to $155.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $144.03.
In other news, insider Lonny J. Carpenter sold 5,000 shares of Stryker Corporation stock in a transaction on Friday, August 4th. The stock was sold at an average price of $146.36, for a total transaction of $731,800.00. Following the sale, the insider now directly owns 88,207 shares in the company, valued at approximately $12,909,976.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Graham A. Mclean sold 1,124 shares of Stryker Corporation stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total value of $164,396.24. Following the sale, the insider now owns 8,983 shares in the company, valued at $1,313,853.58. The disclosure for this sale can be found here. Insiders have sold a total of 32,810 shares of company stock worth $4,754,958 over the last quarter. Company insiders own 7.40% of the company’s stock.
About Stryker Corporation
Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.
Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
